NexImmune, Inc.
NEXIDelisted Sep 6, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001538210
NexImmune, Inc. was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 13 institutions reported holding it in 13F filings for Q2 2024, worth $408.6K in total; no superinvestor held it.
Q3 2024 vs. Q2 2024
How the institutions holding NexImmune, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 13 | 1 | −12 |
| Shares | 148.1K | 10.8K | −137.3K (−92.7%) |
| Value | $408.6K | $2.70K | −$405.9K (−99.3%) |
New holders (0)
Institutions that held NexImmune, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
None.
Sold out (12)
Institutions that held NexImmune, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Sabby Management, LLC | 49,904 | $137.7K |
| Slate Path Capital LP | 36,999 | $102.1K |
| EPIQ Capital Group, LLC | 15,624 | $43.1K |
| The PNC Financial Services Group, Inc. | 12,640 | $34.9K |
| Vanguard Group Inc | 12,010 | $33.1K |
| JPMorgan Chase & Co | 4,000 | $11.1K |
| Comerica Bank | 3,256 | $8.99K |
| Tower Research Capital LLC (TRC) | 2,121 | $5.85K |
| UBS Group AG | 638 | $1.76K |
| BNP Paribas Arbitrage, SA | 41 | $113 |
| Bank of America Corp | 7 | $19 |
| Royal Bank of Canada | 102 | $0 |